Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial.
Frontiers in oncology（2023）
摘要
EudraCT Number: 2020-003008-15, ClinicalTrials.gov identifier: NCT05312398.
更多查看译文
关键词
EGFR,biomarker,cetuximab,colorectal cancer,liquid biopsy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要